2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146574
    AKR1C3-IN-7
    		Inhibitor
    AKR1C3-IN-7 (Compound 13) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.19 μM. AKR1C3-IN-7 shows antitumor activity.
    AKR1C3-IN-7
  • HY-161839
    AKR1C2/3-IN-1
    		Inhibitor
    AKR1C2/3-IN-1 (compound 3a) is a potent AKR1C2 and AKR1C3 inhibitor with IC50 values of 90, 50 nM, respectively. AKR1C2/3-IN-1 can be used as a radiation sensitizer and as a potentiator of chemotherapy cytotoxicity.
    AKR1C2/3-IN-1
  • HY-151947
    ALR2-IN-3
    		Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 22 nM and 116 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.
    ALR2-IN-3
  • HY-150650
    S07-2001
    		Inhibitor
    S07-2001 is a potent and selective aldo-keto reductase 1C3 (AKR1C3) inhibitor with an IC50 value of 2.08 μM. S07-2001 enhances the activity of Doxorubicin against cancer cells. S07-2001 has potential as a chemotherapeutic potentiator for cancer agent resistance.
    S07-2001
  • HY-131542
    APPA
    		Inhibitor
    APPA is an aldose reductase inhibitor. APPA can effectively prevent apoptosis and the symptoms of Streptozotocin (HY-13753)-induced diabetes by inhibiting the polyol pathway in rats. APPA has the potential for diabetic nephropathy (DN) research.
    APPA
  • HY-163610
    AKR1C3-IN-13
    		Inhibitor
    AKR1C3-IN-13 (Compound 4) is an AKR1C3 inhibitor. AKR1C3-IN-13 degrades AKR1C3 in prostate cancer cells.
    AKR1C3-IN-13
  • HY-N11639
    Ganoderic acid Df
    		Inhibitor
    Ganoderic acid Df is a lanostane-type triterpenoid, that can be isolated from the fruiting body of Ganoderma lucidum. Ganoderic acid Df potently inhibits aldose reductase, with an IC50 of 22.8 ± 0.6 μM.
    Ganoderic acid Df
  • HY-106877
    Minalrestat
    		Inhibitor
    Minalrestat (ARI-509) is a potent and orally active aldose reductase inhibitor. Minalrestat can be used in the research of diabetes.
    Minalrestat
  • HY-146129
    Aldose reductase-IN-5
    As an aldose reductase (ALR2) inhibitor, the compound is used to enhance the combination of inhibitory excitability and antioxidant capacity to delay the progress of diabetes complications.
    Aldose reductase-IN-5
  • HY-149255
    PTP1B/AKR1B1-IN-2
    		Inhibitor
    PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM).
    PTP1B/AKR1B1-IN-2
  • HY-147977
    ALR1/2-IN-1
    		Inhibitor
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity.
    ALR1/2-IN-1
  • HY-W601605
    Methosorbinil
    		Inhibitor
    Methosorbinil is an aldose reductase inhibitor with anti-cataract activity.
    Methosorbinil
  • HY-N12862
    Floramanoside A
    		Inhibitor
    Floramanoside A is a flavonol glycoside that can be isolated from the flowers of Abelmouschus manihot. Floramanoside A has DPPH scavenging (IC50: 10.1 μM) and aldose reductase inhibition activities (IC50: 17.8 μM).
    Floramanoside A
  • HY-N9335
    Myrciacetin
    		Inhibitor
    Myrciacetin is a flavonoid from Rhododendron dauricum. Myrciacetin is against rat lens aldose reductase with an IC50 of 13 μM.
    Myrciacetin
  • HY-N3716
    Dehydroglyasperin D
    		Inhibitor
    Dehydroglyasperin D inhibits rat and human Aldose Reductase (AR) (IC50: 62.4 μM and 176.2 μM respectively). Dehydroglyasperin D has anti-obesity, antioxidant effects. Dehydroglyasperin D shows anti-inflammatory activity by inhibiting COX-2 expression and the MLK3 signaling pathway. Dehydroglyasperin D also inhibits melanin synthesis. Dehydroglyasperin D is a prenylated flavonoid that can be isolated from Glycyrrhiza uralensi.
    Dehydroglyasperin D
  • HY-175331
    ALR2-IN-7
    		Inhibitor 99.94%
    ALR2-IN-7 (Compound 5a) is a highly potent and selective aldose reductase (ALR2/AKR1B1) inhibitor (Ki=8.71 nM). ALR2-IN-7 is promising for research of diabetic complications (e.g., retinopathy, nephropathy) and cancers.
    ALR2-IN-7
  • HY-146575
    AKR1C3-IN-8
    		Inhibitor
    AKR1C3-IN-8 (Compound 5) is a potent, selective AKR1C3 inhibitor with an IC50 of 0.069 μM. AKR1C3-IN-8 shows antitumor activity.
    AKR1C3-IN-8
  • HY-146661
    Aldose reductase-IN-4
    		Inhibitor
    Aldose reductase-IN-4 (compund IIc) is an aldose reductase inhibitor with IC50s of 11.70 μM and 0.98 μM for aldehyde reductase 1 (ALR1) and ALR2, respectively.
    Aldose reductase-IN-4
  • HY-146573
    AKR1C3-IN-6
    		Inhibitor
    AKR1C3-IN-6 (Compound 1) is a potent, selective AKR1C3 inhibitor with IC50 values of 0.31 μM and 73.23 μM against AKR1C3 and AKR1C2, respectively. AKR1C3-IN-6 shows antitumor activity.
    AKR1C3-IN-6
  • HY-163784
    AKR1C3-IN-14
    		Inhibitor
    AKR1C3-IN-14 (compound 4) is an AKR1C3 inhibitor (IC50=0.122 μM) that reduces the overproduction of androgens by inhibiting the activity of the AKR1C3 enzyme, thereby regulating hormone-mediated signaling. AKR1C3-IN-14 also plays a role in the biosynthesis of the prostaglandin PGF2α, regulating cell proliferation by affecting this pathway. AKR1C3-IN-14 can be used in the study of prostate cancer.
    AKR1C3-IN-14
Cat. No. Product Name / Synonyms Application Reactivity